BioLineRx logo

BioLineRxNASDAQ: BLRX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Israel

IPO:

27 July 2011

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$33.58 M
-77%vs. 3y high
30%vs. sector
-vs. 3y high
-vs. sector
-76%vs. 3y high
62%vs. sector
-92%vs. 3y high
38%vs. sector

Price

pre-market | 3 min ago
$0.42-$0.11(-20.77%)

Dividend

No data over the past 3 years
$5.39 M$5.29 M
$5.39 M$484.00 K

Analysts recommendations

Institutional Ownership

BLRX Latest News

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
prnewswire.com21 November 2024 Sentiment: POSITIVE

– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23% – – BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC –  – BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion – – Trans actions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases – – BioLineRx will provide further corporate updates on its Q3 results conference call, which is scheduled for November 25 at 8:30 am ET – TEL AVIV, Israel , Nov. 21, 2024 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection
prnewswire.com17 September 2024 Sentiment: POSITIVE

Patient survey currently underway in partnership with the HealthTree Foundation; data expected in Q1 2025 TEL AVIV, Israel and WALTHAM, Mass. , Sept. 17, 2024 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript
seekingalpha.com15 August 2024 Sentiment: NEUTRAL

BioLineRx Ltd. (NASDAQ:BLRX ) Q2 2024 Earnings Conference Call August 15, 2024 8:30 AM ET Company Participants John Lacey - Head of IR and Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO Ella Sorani - Chief Development Officer Conference Call Participants John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by.

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
prnewswire.com15 August 2024 Sentiment: POSITIVE

- Secured APHEXDA® formulary placement among top 80 transplant centers representing ~37% of stem cell transplant procedures performed, surpassing stated goal for quarter; on-track to reach goal of ~60% by end of Q4 - - Doubled the number of centers ordering APHEXDA during the second quarter - - Entered into clinical trial agreement with St. Jude Children's Research Hospital to evaluate motixafortide for hematopoietic stem cell mobilization for gene therapies in sickle cell disease - - Management to host conference call today, August 15, at 8:30 am EDT - TEL AVIV, Israel , Aug. 15, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the second quarter ended June 30, 2024, and provided recent corporate and portfolio updates.

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
prnewswire.com28 May 2024 Sentiment: POSITIVE

- Steady growth in APHEXDA ®  adoption in first full quarter post-approval - - Among top 80 transplant centers, secured APHEXDA formulary placement to date at institutions representing ~26% of stem cell transplant procedures performed - on track to reach stated goal of ~35% by end of Q2 - - Announced new data in abstract accepted at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting on pilot phase of ongoing Phase 2b pancreatic cancer clinical trial collaboration with Columbia University  - - Collaboration partner Gloria Biosciences' motixafortide HSC mobilization bridging study IND was filed and approved by the Center for Drug Evaluation of the National Medical Products Administration in China. Anticipate clinical trial initiation 2H 2024 - - Completed debt and equity financing totaling $26 million to support U.S. commercialization of APHEXDA and advance lifecycle expansion activities  - - Management to host conference call today, May 28, at 8:30 am EDT - TEL AVIV, Israel , May 28, 2024 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
prnewswire.com17 May 2024 Sentiment: NEGATIVE

BioLineRx Ltd., a biopharmaceutical company focusing on oncology and rare diseases, has received a notification letter from Nasdaq.

3 Top Penny Stocks for 5,000% Upside in 2024 and Beyond
InvestorPlace25 February 2024 Sentiment: NEGATIVE

In almost every situation, investors should stay away from penny stocks. They're extremely speculative and they tend to facilitate delusions of grandeur.

BioLineRx: Still A Buy, With Some Questions
Seeking Alpha04 December 2023 Sentiment: POSITIVE

BioLineRx gains approval for a blood cancer drug that aids in stem cell transplantation. Motixafortide, the flagship drug, shows promising results in mobilizing blood stem cells and in combination with other treatments for pancreatic cancer. Financially, BioLineRx has a limited amount of cash on hand but has secured a licensing deal that provides additional funds.

BioLineRx: Weighing Aphexda's Breakthrough Against Financial Challenges
Seeking Alpha02 December 2023 Sentiment: POSITIVE

BioLineRx is a biopharmaceutical company specializing in cancer and rare disease therapies. The company's main product, Aphexda, was FDA-approved for stem cell mobilization in multiple myeloma patients. BioLineRx's low cash reserves and need for additional financing pose risks, but its valuation appears relatively conservative.

BioLineRx Ltd. (BLRX) Q3 2023 Earnings Call Transcript
Seeking Alpha20 November 2023 Sentiment: NEUTRAL

BioLineRx Ltd. (NASDAQ:BLRX ) Q3 2023 Earnings Conference Call November 20, 2023 10:00 PM ET Company Participants John Lacey - Head of IR & Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO Conference Call Participants Joe Pantginis - H.C.

What type of business is BioLineRx?

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

What sector is BioLineRx in?

BioLineRx is in the Healthcare sector

What industry is BioLineRx in?

BioLineRx is in the Biotechnology industry

What country is BioLineRx from?

BioLineRx is headquartered in Israel

When did BioLineRx go public?

BioLineRx initial public offering (IPO) was on 27 July 2011

What is BioLineRx website?

https://www.biolinerx.com

Is BioLineRx in the S&P 500?

No, BioLineRx is not included in the S&P 500 index

Is BioLineRx in the NASDAQ 100?

No, BioLineRx is not included in the NASDAQ 100 index

Is BioLineRx in the Dow Jones?

No, BioLineRx is not included in the Dow Jones index

When was BioLineRx the previous earnings report?

No data

When does BioLineRx earnings report?

Next earnings report date is not announced yet